Phase 2 N=87 Effects of Vivatlac Baby on Crying Behavior of Colicky Babies
Infantile Colic
Primary: Number of Participants With a Reduction of Days Crying Equal or More Than 50 Percent From Baseline — 6; 39 Participants — p=<0.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=180 Efficacy of Matricariae Chamomilla L., Melissa Officinalis L. and Tyndallized Lactobacillus Acidophilus (H122) for Infantile Colics
Infantile Colics
Primary: Median Daily Crying Time at the End of the Treatment — 50; 55; 80 minutes
N/A N=80 Clinical Trial to Evaluate the Efficacy of Bifidobacterium BB-12® in the Treatment of Infantile Colic
Infantile Colic · Colic, Infantile
Primary: Number of Participants With >=50% Reduction in Mean Weekly Crying Duration — 32; 13; 3; 24 Participants — p=0.0001
Phase 2 N=90 Effects of Acupuncture in the Treatment of Infant Colic
Infant Colic
Primary: Change in Crying Time Per 24 Hour Period. — 220; 212; 230; 186 minutes crying time pr 24 hour
N/A N=30 Effect of Lactobacillus Rhamnosus GG (LGG) on Infant Colic
Colic · Inflammation
Primary: Daily Average Crying and Fussing Duration According to Barr Diary Records — 111; 133 minutes
Phase 2 N=115 Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant Colic
Infantile Colic
Primary: Absolute Change of the Mean Daily Crying and Fussing Time for Three Consecutive Days While on Treatment Versus Baseline. — 284.57; 273.6; 283.91; 185.8 Minutes
Phase 4 N=20 INF108F in Infants With Food Protein Induced Proctocolitis
Infant Development · Gut Microbiome · Food Protein Induced Allergic Proctocolitis
Primary: Changes to Gut Microbiome Composition — 42.816; -12.413 Change in %B.infantis reads (Day 28-BL) — p=0.154
Phase 4 N=96 Impact of Oral Application of Gastrografin on the Meconium Evacuation in Very Low Birth Weight Infants
Meconium Ileus · Very Low Birth Weight Infant
Primary: Time to Complete Meconium Evacuation in Days — 7; 8 days of life — p=0.61
N/A N=24 Probiotics in Infants With Gastroschisis
Gastroschisis
Primary: Composition of the Fecal Microbiota — 42; 12; 1.1; 14 percentage of total bacteria — p=<0.01
N/A N=51 An Intervention to Decrease Infant Crying
Colic
Primary: Hours Per Day of Fuss/Cry — 2.20; 1.48 hours per day
Phase 2 N=27 Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance
Colic
Primary: The Absolute Differences of I-GERQ-R Total Score at V3 (End of First Week of Treatment) Respect to the Baseline (V2). — -6.8; -7.6; -6.8 score on a scale
N/A N=102 Maintenance Treatment for Children With Constipation
Constipation
Primary: Treatment Recovery — 33; 19 participants — p=0.024
N/A N=76 Neonatal Gastro-Esophageal Reflux Disease (GERD) Management Trial
Gastroesophageal Reflux Disease
Primary: CLINICAL OUTCOME OF FEEDING SUCCESS — 33; 44 percentage of participants — p=0.28
N/A N=94 Lcr35 for Children With Functional Constipation
Constipation
Primary: Number of Participants With Treatment Success (≥3 Spontaneous Defecations Per Week With no Fecal Soiling — 24; 28 Participants — p=0.399
N/A N=22 Effect of Inulin-type Fructans on Constipated Children.
Constipation
Primary: Stool Consistency — 2.57; 1.63 units on a scale
N/A N=31 Efficacy of Open Label Placebo in Children With FGIDs
Functional Abdominal Pain · Functional Dyspepsia · Irritable Bowel Syndrome
Primary: The Primary Outcome Measure Was Mean Daily Pain — 39.9; 45.14 pain scale by VAS in mm — p=<0.03
Phase 3 N=81 Anxiety and Recurrent Abdominal Pain in Children
Abdominal Pain · Anxiety
Primary: Clinical Global Impression Scale - Improvement (CGI-I) Will be Used to Assess Overall Global Illness Improvement. CGI-I Scores of 1 (Very Much Improved) or 2 (Much…
Phase 1 N=41 Chewing Gum Use to Reduce Post-operative Ileus in Pediatric Patients
Post Operative Ileus
Primary: Post-Operative Hospital Stay — 79.93; 72.94 hours — p=0.665
N/A N=72 Physiotherapeutic Intervention in Children With Chronic Functional Constipation
Chronic Constipation
Primary: Frequency of Defecation. — 3.9; 5.1 days/week — p=<0.05
Phase 4 N=153 The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation
Functional Constipation
Primary: Change of Clostridium Butyricum Miyairi Expression After Probiotics Supplementation in Constipated Children. — 0.00486; 0.0000148; 0.00000189 number of bacteria per mg…
Phase 3 N=18 Medical Treatment for Gastroesophageal Reflux Disease (GERD) in Preterm Infants
Gastroesophageal Reflux
Primary: Bradycardia Episodes/Day — 4.6; 3.6 episodes per day
Phase 1 N=44 Intestinal Permeability in Preterm Infants
Prematurity · Intestinal Permeability
Primary: Intestinal Permeability — 0.0731; 0.0720 ratio — p=0.932
Phase 2 N=19 A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide
Functional Constipation
Primary: Change From Baseline in Overall Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) During the Study Intervention Period — 3.181; 2.503; 0.246; 3.371 SBMs/Week
N/A N=90 Effects of Probiotic and Prebiotic Combinations on Premature Infants
Premature Infants · Stool Bacterial Composition · Growth
Primary: Weight Gain — 618; 590; 682 Grams — p=>0.5
N/A N=96 Study of Stool Patterns to Collect a Panel of Stool Images for the Development of a Software
Healthy
Primary: Total Number of Stool Images Collected — 2731 images
Phase 3 N=123 A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation
Functional Constipation (FC) · Chronic Idiopathic Constipation (CIC)
Primary: Change From Baseline in 12-week Spontaneous Bowel Movement (SBM) Frequency Rate (SBMs/Week) Observed by the Primary Caregiver During the Double-blind Study Intervention…
Phase 2 N=18 Early Supplementation of Enteral Microlipid With and Without Fish Oil in Premature Infants With Enterostomies
Prematurity · Intestine Perforation · Necrotizing Enterocolitis (NEC)
Primary: The Serum Biomarkers of Inflammatory Cytokines
Phase 3 N=215 Prucalopride in Pediatric Subjects With Functional Constipation
Functional Constipation
Primary: Percent of Responders in the Last Four Weeks of the Double-Blind Treatment Period — 17.0; 17.8 percentage of subjects — p=0.9002
Phase 2 N=134 Prophylactic Probiotics to Extremely Low Birth Weight Prematures
Feeding; Difficult, Newborn · Growth Failure · Necrotizing Enterocolitis
Primary: Time to Establish Full Enteral Feeds — 15; 15 days
N/A N=79 Glycerin Suppositories to Reduce Jaundice in Premature Infants
Idiopathic Hyperbilirubinemia · Neonatal Hyperbilirubinemia · Prematurity
Primary: Total Number of Hours of Required Phototherapy — 72; 61 hours